Abel Torrelles Fortuny

Médico, Cardiólogo , HGTiP👨🏽‍⚕ Lleida - Santiago - Barcelona. “Never stop learning”

[Guilherme Teló @guilhermehtelo]

🚨 Excited to share our latest publication! 🫀🔍. ΔVExPLUs integrates serial changes in VExUS and LUS, providing improved prognostic assessment in ADHF and offering a potential framework for ultrasound-guided, phenotype-based decongestive management.

: https://t.co/tSbNbuwHIR

[NephroPOCUS @NephroP]

#POCUS #Nephpearls
Long-Term Prognostic Implications of #VExUS in Acute Heart Failure.
"ready for discharge" doesn't always mean decongested. In 428 acute HF patients, the 1-year risk of death/HF readmission was 25% with VExUS 0 vs 69% with VExUS 3 at discharge. VExUS provided incremental prognostic information beyond standard clinical and echo markers.
🔗 in thread.

[Kosmos LATAM by EchoNous @KosmosLatAm]

Faltan 2 días para nuestro próximo webinar
Un espacio diseñado para compartir conocimiento, práctica clínica y el valor del POCUS en la toma de decisiones.
Últimos lugares disponibles. ¡Regístrate ahora!
#Webinar #EducaciónMédica #KosmosByEchoNous

[Abel Torrelles Fortuny @abel_torrelles]

@NephroP Suprahepatic vein

[Eduardo R Argaiz @ArgaizR]

Nos vemos el 14 de Mayo!

Webinar gratuito

Registro: https://t.co/TMO6CKvlXl

[NEJM @NEJM]

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @tuftsmedschool and the Maine Medical Center Institute for Research: https://t.co/D0XSLv7U8n

[NEJM @NEJM]

Presented at #ACC26:

Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results: https://t.co/q0vNdAoJJL

Editorial: Paving the Road toward Targeted Lipid Lowering https://t.co/zUwmo0r0n4

@ACCinTouch

[Abel Torrelles Fortuny @abel_torrelles]

@GustavoBolsa Hola @GustavoBolsa gran notícia la publicación de este libro, deseando leerlo. Quería preguntar si harás presentación del mismo en Madrid o Barcelona ?

[NEJM @NEJM]

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results: https://t.co/qAMC2o36Mi

Editorial: Left Atrial Appendage Closure — Another Overused Method in Cardiology? https://t.co/KyOWdblUR3

[Aitor Uribarri @Auribarri]

#Delirium is not “just confusion”, it is a major prognostic event in CV medicine.
In our State-of-the-Art Review in #EHJ, we synthesize current evidence on mechanisms, prevention, and management across the CV continuum. 🧠🫀
https://t.co/l4VSzuTQDL
@CekajEndrit et al👏👏

[Sripal Bangalore @SripalBangalore]

Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel CAD https://t.co/ECxuftCm59. @SVRaoMD @glennfishman @DFCapodanno @mmamas1973 @realarainmd @mirvatalasnag @RizikMd @sbrugaletta @drjohnm

[Abel Torrelles Fortuny @abel_torrelles]

@NephroP 1 Pericardial effusion, 2 aorta

[NEJM @NEJM]

Original Article: Beta-blockers after Myocardial Infarction with Normal Ejection Fraction https://t.co/1LiJFFvnm3

@AHAScience | #AHA25

[NEJM @NEJM]

Presented at #AHA25:

In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: https://t.co/1LiJFFvnm3

@AHAScience

[ShadowsOfConstantinople @RomeInTheEast]

Is this what forever looks like

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Sepsis-induced cardiomyopathy: @ESC_Journals

🥸 Nicely done: please read full article - very useful.

😱 Here is the summary

👇👇👇

[Soc Esp Cardiología @secardiologia]

👩‍💻🧑‍💻Cuatro días intensos de trabajo de @C_Boillot, @Laurynumar, @drassantos y @abel_torrelles para presentar las novedades de las guías de práctica clínica y los estudios presentados en ESC Congress 2025, y que puedes ver en #LaSECteLleva.

Y mañana, análisis post con @almucastro01 , @miguelcainzos23, @MonzonisAmparo y @maruor2014.

🔗https://t.co/qkBjZzLDab

[Almudena Castro Conde @almucastro01]

Agradecer públicamente el trabajazo del equipo IN de #LaSECteLleva para traernos día a día los resúmenes casi simultáneos de los estudios y guías presentados en este #ESC25
Gracias @drassantos @Laurynumar @abel_torrelles @C_Boillot @AliciaItuarte @Lindaonti y todo el equipo de @secardiologia @anguita_m
Puedes ver los vídeos en

https://t.co/Cbsm4LkFKC

[Soc Esp Cardiología @secardiologia]

Seguimos en #laSECtelleva revisando los principales resultados presentados en #ESC25.

📝 Repasa las claves de las nuevas guías europeas de dislipemias y el resto de resúmenes express con @Laurynumar, @abel_torrelles, @drassantos y @C_Boillot.

https://t.co/J0mX3RfLUO